EAT is up +49.38%% since April’24 pick View All Top Buy Picks

Oyster Point Pharma Inc Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -27.66. In total, the insiders bought 1 389 418 and sold 22 126 304 OYST shares in the last 100 trades.

Insider Power

(Last 100 transactions)
-27.66
Buy 1 389 418 Shares
Sell 22 126 304 Shares

Historical Insider Trades

Date Type Action Person Amount
Jan 03, 2023 Common Stock, par value $0.001 per share Sell Invopps Gp Iv, L.l.c. 1 850 818
Jan 03, 2023 Common Stock, par value $0.001 per share Sell Invopps Gp Iv, L.l.c. 1 850 818
Jan 03, 2023 Common Stock Sell Versant Venture Capital Vi, L.p. 1 003 658
Jan 03, 2023 Common Stock Sell Versant Venture Capital Vi, L.p. 1 003 658
Jan 03, 2023 Common Stock Sell Behbahani Ali 10 066
Jan 03, 2023 Stock Option (Right to Buy) Sell Behbahani Ali 5 199
Jan 03, 2023 Common Stock Sell New Enterprise Associates 14, L.p. 5 925 287
Jan 03, 2023 Common Stock Sell New Enterprise Associates 14, L.p. 5 925 287
Jan 03, 2023 Common Stock Sell Weisner Aimee S 33 191
Jan 03, 2023 Stock Option (Right to Buy) Sell Weisner Aimee S 5 199
Jan 03, 2023 Common Stock Sell Tsai Benjamin 10 066
Jan 03, 2023 Stock Option (Right to Buy) Sell Tsai Benjamin 5 199
Jan 03, 2023 Common Stock Sell Santel Donald J 5 489
Jan 03, 2023 Stock Option (Right to Buy) Sell Santel Donald J 5 359
Jan 03, 2023 Common Stock Sell Ozawa Clare 11 064
Jan 03, 2023 Stock Option (Right to Buy) Sell Ozawa Clare 5 199
Jan 03, 2023 Common Stock Sell Ozawa Clare 1 003 658
Jan 03, 2023 Common Stock Sell Nau Jeffrey 100 738
Jan 03, 2023 Stock Option (Right to Buy) Sell Nau Jeffrey 210 000
Jan 03, 2023 Common Stock Sell Murray Mark Anthony 118 513
Jan 03, 2023 Stock Option (Right to Buy) Sell Murray Mark Anthony 5 359
Jan 03, 2023 Common Stock Sell Lochner Daniel 56 289
Jan 03, 2023 Stock Option (Right to Buy) Sell Lochner Daniel 87 900
Jan 03, 2023 Common Stock Sell Eliades George Christopher 11 761
Jan 03, 2023 Stock Option (Right to Buy) Sell Eliades George Christopher 5 199
Click to get the best stock tips daily for free!

About Oyster Point Pharma Inc

Oyster Point Pharma Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for ... OYST Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT